A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells

Kaltschmidt C, Banz-Jansen C, Benhidjeb T, Beshay M, Förster C, Greiner J, Hamelmann E, Jorch N, Mertzlufft F, Pfitzenmaier J, Simon M, et al. (2019)
Cancers 11(5): 655.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 912.27 KB
Autor*in
Kaltschmidt, ChristianUniBi; Banz-Jansen, Constanze; Benhidjeb, Tahar; Beshay, Morris; Förster, Christine; Greiner, JohannesUniBi ; Hamelmann, Eckard; Jorch, Norbert; Mertzlufft, Fritz; Pfitzenmaier, Jesco; Simon, Matthias; Schulte am Esch, Jan
Alle
Abstract / Bemerkung
Cancer stem cells (CSCs) account for tumor initiation, invasiveness, metastasis, and recurrence in a broad range of human cancers. Although being a key player in cancer development and progression by stimulating proliferation and metastasis and preventing apoptosis, the role of the transcription factor NF-κB in cancer stem cells is still underestimated. In the present review, we will evaluate the role of NF-κB in CSCs of glioblastoma multiforme, ovarian cancer, multiple myeloma, lung cancer, colon cancer, prostate cancer, as well as cancer of the bone. Next to summarizing current knowledge regarding the presence and contribution of CSCs to the respective types of cancer, we will emphasize NF-κB-mediated signaling pathways directly involved in maintaining characteristics of cancer stem cells associated to tumor progression. Here, we will also focus on the status of NF-κB-activity predominantly in CSC populations and the tumor mass. Genetic alterations leading to NF-κB activity in glioblastoma, ependymoma, and multiple myeloma will be discussed.
Stichworte
cancer stem cells; NF-κB; glioblastoma multiforme; pediatric cancer; ovarian cancer; multiple myeloma; lung cancer; colon cancer; prostate cancer; bone cancer
Erscheinungsjahr
2019
Zeitschriftentitel
Cancers
Band
11
Ausgabe
5
Art.-Nr.
655
ISSN
2072-6694
eISSN
2072-6694
Page URI
https://pub.uni-bielefeld.de/record/2935594

Zitieren

Kaltschmidt C, Banz-Jansen C, Benhidjeb T, et al. A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers. 2019;11(5): 655.
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., et al. (2019). A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers, 11(5), 655. doi:10.3390/cancers11050655
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019). A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers 11:655.
Kaltschmidt, C., et al., 2019. A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers, 11(5): 655.
C. Kaltschmidt, et al., “A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells”, Cancers, vol. 11, 2019, : 655.
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., Simon, M., Schulte am Esch, J., Vordemvenne, T., Wähnert, D., Weissinger, F., Wilkens, L., Kaltschmidt, B.: A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. Cancers. 11, : 655 (2019).
Kaltschmidt, Christian, Banz-Jansen, Constanze, Benhidjeb, Tahar, Beshay, Morris, Förster, Christine, Greiner, Johannes, Hamelmann, Eckard, Jorch, Norbert, Mertzlufft, Fritz, Pfitzenmaier, Jesco, Simon, Matthias, Schulte am Esch, Jan, Vordemvenne, Thomas, Wähnert, Dirk, Weissinger, Florian, Wilkens, Ludwig, and Kaltschmidt, Barbara. “A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells”. Cancers 11.5 (2019): 655.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-05-15T09:03:24Z
MD5 Prüfsumme
58481ffc57991d8befcc8c646b428841

160 References

Daten bereitgestellt von Europe PubMed Central.

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE., Nature 367(6464), 1994
PMID: 7509044
The NF-kappaB family of transcription factors and its regulation.
Oeckinghaus A, Ghosh S., Cold Spring Harb Perspect Biol 1(4), 2009
PMID: 20066092
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM., J. Clin. Oncol. 27(9), 2009
PMID: 19224846
A phase 3 trial of bevacizumab in ovarian cancer.
a, N. Engl. J. Med. 365(26), 2011
PMID: 22204725
Ovarian cancer stem cells: A target for oncological therapy.
Markowska A, Sajdak S, Huczynski A, Rehlis S, Markowska J., Adv Clin Exp Med 27(7), 2018
PMID: 29938937
Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells.
Parajuli B, Lee HG, Kwon SH, Cha SD, Shin SJ, Lee GH, Bae I, Cho CH., Cancer Epidemiol 37(4), 2013
PMID: 23545383
Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).
Hoogstad-van Evert J, Bekkers R, Ottevanger N, Schaap N, Hobo W, Jansen JH, Massuger L, Dolstra H., Medicine (Baltimore) 98(5), 2019
PMID: 30702598
Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling.
Tang S, Xiang T, Huang S, Zhou J, Wang Z, Xie R, Long H, Zhu B., Cancer Lett. 376(1), 2016
PMID: 27033454
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.
House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, Annunziata CM., Cancer Res. 77(24), 2017
PMID: 29074539
NF-κB Participates in the Stem Cell Phenotype of Ovarian Cancer Cells.
Gonzalez-Torres C, Gaytan-Cervantes J, Vazquez-Santillan K, Mandujano-Tinoco EA, Ceballos-Cancino G, Garcia-Venzor A, Zampedri C, Sanchez-Maldonado P, Mojica-Espinosa R, Jimenez-Hernandez LE, Maldonado V., Arch. Med. Res. 48(4), 2017
PMID: 28886875
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA., Haematologica 102(9), 2017
PMID: 28550183
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M., Science 293(5534), 2001
PMID: 11520989
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS., Blood 128(9), 2016
PMID: 27458004
CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements.
Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM., Blood 89(5), 1997
PMID: 9057669
The myeloma stem cell concept, revisited: from phenomenology to operational terms.
Johnsen HE, Bogsted M, Schmitz A, Bodker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K., Haematologica 101(12), 2016
PMID: 27903712
Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells.
Derudder E, Herzog S, Labi V, Yasuda T, Kochert K, Janz M, Villunger A, Schmidt-Supprian M, Rajewsky K., Proc. Natl. Acad. Sci. U.S.A. 113(18), 2016
PMID: 27099294
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation.
Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K, Schmidt-Supprian M., Immunity 24(6), 2006
PMID: 16782029
c-Rel and its many roles in cancer: an old story with new twists.
Hunter JE, Leslie J, Perkins ND., Br. J. Cancer 114(1), 2016
PMID: 26757421
The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND., Oncogene 35(26), 2015
PMID: 26522720
A new scoring system for predicting survival in patients with non-small cell lung cancer.
Schild SE, Tan AD, Wampfler JA, Ross HJ, Yang P, Sloan JA., Cancer Med 4(9), 2015
PMID: 26108458
Identification of bronchioalveolar stem cells in normal lung and lung cancer.
Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T., Cell 121(6), 2005
PMID: 15960971
Stem cells for lung cancer?
Berns A., Cell 121(6), 2005
PMID: 15960966
NF-κB, an active player in human cancers.
Xia Y, Shen S, Verma IM., Cancer Immunol Res 2(9), 2014
PMID: 25187272
Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.
Xu X, Rock JR, Lu Y, Futtner C, Schwab B, Guinney J, Hogan BL, Onaitis MW., Proc. Natl. Acad. Sci. U.S.A. 109(13), 2012
PMID: 22411819
Cell of origin of lung cancer.
Hanna JM, Onaitis MW., J Carcinog 12(), 2013
PMID: 23599688
The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2.
Xu X, Huang L, Futtner C, Schwab B, Rampersad RR, Lu Y, Sporn TA, Hogan BL, Onaitis MW., Genes Dev. 28(17), 2014
PMID: 25184679
Nuclear factor-κB: a key regulator in health and disease of lungs.
Batra S, Balamayooran G, Sahoo MK., Arch. Immunol. Ther. Exp. (Warsz.) 59(5), 2011
PMID: 21786215
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target.
Chen W, Li Z, Bai L, Lin Y., Front Biosci (Landmark Ed) 16(), 2011
PMID: 21196225
Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z, Guo C., Ann. Surg. Oncol. 14(12), 2007
PMID: 17899287
Prognostic significance of RelB overexpression in non-small cell lung cancer patients.
Qin H, Zhou J, Zhou P, Xu J, Tang Z, Ma H, Guo F., Thorac Cancer 7(4), 2016
PMID: 27385983
Inhibition of NF-κB Signaling Reduces the Stemness Characteristics of Lung Cancer Stem Cells.
Zakaria N, Mohd Yusoff N, Zakaria Z, Widera D, Yahaya BH., Front Oncol 8(), 2018
PMID: 29868483
The complexity of NF-κB signaling in inflammation and cancer.
Hoesel B, Schmid JA., Mol. Cancer 12(), 2013
PMID: 23915189
Primary prevention of colorectal cancer.
Chan AT, Giovannucci EL., Gastroenterology 138(6), 2010
PMID: 20420944
Ulcerative colitis and colorectal cancer. A population-based study.
Ekbom A, Helmick C, Zack M, Adami HO., N. Engl. J. Med. 323(18), 1990
PMID: 2215606
Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers.
Delaney CP, Lavery IC, Brenner A, Hammel J, Senagore AJ, Noone RB, Fazio VW., Ann. Surg. 236(2), 2002
PMID: 12170025
Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands.
Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group., Br J Surg 89(9), 2002
PMID: 12190680
Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome.
Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S., Colorectal Dis 11(4), 2009
PMID: 19016817
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T., N. Engl. J. Med. 378(13), 2018
PMID: 29590544
Systemic treatment of colorectal cancer.
Wolpin BM, Mayer RJ., Gastroenterology 134(5), 2008
PMID: 18471507
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H., Nature 459(7244), 2009
PMID: 19329995
Subunit-Specific Role of NF-κB in Cancer.
Kaltschmidt B, Greiner JFW, Kadhim HM, Kaltschmidt C., Biomedicines 6(2), 2018
PMID: 29673141
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.
Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP., Proc. Natl. Acad. Sci. U.S.A. 105(36), 2008
PMID: 18765800
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties.
Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, Rupec RA, Gerhard M, Schmid R, Barker N, Clevers H, Lang R, Neumann J, Kirchner T, Taketo MM, van den Brink GR, Sansom OJ, Arkan MC, Greten FR., Cell 152(1-2), 2012
PMID: 23273993
AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment.
Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS., Cancer Res. 70(19), 2010
PMID: 20823151
Down-regulation of CDH1 is associated with expression of SNAI1 in colorectal adenomas.
Kroepil F, Fluegen G, Totikov Z, Baldus SE, Vay C, Schauer M, Topp SA, Esch JS, Knoefel WT, Stoecklein NH., PLoS ONE 7(9), 2012
PMID: 23029563
Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer.
Min J, Liu L, Li X, Jiang J, Wang J, Zhang B, Cao D, Yu D, Tao D, Hu J, Gong J, Xie D., Sci Rep 5(), 2015
PMID: 26564738
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D, Fu L, Sun H, Guo L, DuBois RN., Gastroenterology 149(7), 2015
PMID: 26261008
Cancer statistics, 2019.
Siegel RL, Miller KD, Jemal A., CA Cancer J Clin 69(1), 2019
PMID: 30620402
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators, Kirkels WJ, Rietbergen JB, van der Cruijsen IW, Raaijmakers R, de Vries SH, Roemeling S, Gosselaar C, Wolters T, van den Bergh RC, van Leeuwen PJ, Bul M, Zhu X, van Vugt HA, Bokhorst LP, Salman JW, Venderbos LD, Yurdakul G, Boeken-Kruger A, Wijburg C, Forouzanfor M, de Boer M, Postma R, Vis AN, Hoedemaeker R, van Leenders A, Blijenberg B, van der Maas PJ, Otto S, Draisma G, Beemsterboer P, Essink-Bot M, Korfage I, Boer R, Wildhagen M, Heijnsdijk E, Merkelbach W, Hoekstra W, Blom J, Damhuis RA, Reedijk A, Kranse R, Roobol DW, Roobol W, van den Berg E, de Zwart GJ, Franken-Raab CG, van Slooten-Midderig M, Smit A, van der Drift V, de Bilde E, Mani L, Visser-van Dongen M, Versteeg-Leenheer H, Zoutendijk B, Vink N, van Meurs H, de Bruijn AE, Devriendt H, Thijs G, Hermans A, D'Hooge K, Neels H, Wauters A, Neetens I, Kockx M, Keuppens F, Braeckman J, Govaerts F, Spinnewijn B, Van Hoey M, Putzeys T, De Coninck M, Dourcy-Belle-Rose B, Vancauwenbergh A, Coebergh JW, Verhaegen H, Van Vliet , Standaert B, Van Herck L, Nyberg M, Bergdahl S, Lodding P, Khatami A, Stranne J, Ahlgren H, Eriksson GB, Al-Battat MH, Erlandsson A, Carlsson S, Grenabo A, Godtman R, Pettersson S, Varenhorst E, Norlen BJ, Zackrisson B, Holmberg E, Frosing R, Pileblad E, Pihl CG, Laurila M, Aro J, Juusela H, Mildh M, Lahtela J, Karhunen PJ, Makinen T, Rannikko A, Malila N, Kilpelainen T, Murtola T, Rannikko S, Ruutu M, Ala-Opas M, Kuivalainen S, Karhunen T, Leinimaa M, Saarinen J, Cappellini M, Bianchi S, Lombardi C, Bussotti A, Bastiani P, Di Lollo S, Manneschi G, Crocetti E, Bonardi R, Rubeca T, Detti B, Berenguer A, Rodriguez JA, Aybar B, Angulo JC, Granados R, Seiler D, Baumgartner M, Randazzo M, Tscholl R, Woodtli E, Scharer L, Herklotz R, Stamm B, Wernli M, Bodis S, Grobholz R, Lehmann K, Schmid HR, Iselin HU, Bubendorf L, Wyler S, Steurer J, Kurrer M, Malavaud B, Iborra F, Malavaud S, Grosclaude P, Tretarre B, Bataille V, Bessaoud F, Neville M, Van der Kwast T, van Leenders GJ, Hoedemaeker RF, Pihl CG, Martikainen PM, Laurila M, Bubendorf L, Santonja C, Neetens I, DiLollo S, Mazerolles C., Lancet 384(9959), 2014
PMID: 25108889
The Direct and Indirect Roles of NF-κB in Cancer: Lessons from Oncogenic Fusion Proteins and Knock-in Mice.
Riedlinger T, Haas J, Busch J, van de Sluis B, Kracht M, Schmitz ML., Biomedicines 6(1), 2018
PMID: 29562713
Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Haggman M, Andersson SO, Andren O, Steineck G, Adami HO, Johansson JE., N. Engl. J. Med. 379(24), 2018
PMID: 30575473
A luminal epithelial stem cell that is a cell of origin for prostate cancer.
Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM., Nature 461(7263), 2009
PMID: 19741607
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling.
Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI., Nat Commun 2(), 2011
PMID: 21245843
Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.
Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry PA, Hyde CF, Lewis JL, Stower MJ, Maitland NJ, Collins AT., Genome Biol. 9(5), 2008
PMID: 18492237
PSCA regulates IL-6 expression through p38/NF-κB signaling in prostate cancer.
Liu L, Li E, Luo L, Zhao S, Li F, Wang J, Luo J, Zhao Z., Prostate 77(14), 2017
PMID: 28845520
Cancer stem cells in osteosarcoma.
Brown HK, Tellez-Gabriel M, Heymann D., Cancer Lett. 386(), 2016
PMID: 27894960
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas.
Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C., Oncogene 31(18), 2011
PMID: 21927024
Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance.
Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T., Oncol. Rep. 24(2), 2010
PMID: 20596639
CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle.
Slotta C, Schluter T, Ruiz-Perera LM, Kadhim HM, Tertel T, Henkel E, Hubner W, Greiner JFW, Huser T, Kaltschmidt B, Kaltschmidt C., PLoS ONE 12(8), 2017
PMID: 28767691
IKK1/2 protect human cells from TNF-mediated RIPK1-dependent apoptosis in an NF-κB-independent manner.
Slotta C, Storm J, Pfisterer N, Henkel E, Kleinwachter S, Pieper M, Ruiz-Perera LM, Greiner JFW, Kaltschmidt B, Kaltschmidt C., Biochim Biophys Acta Mol Cell Res 1865(8), 2018
PMID: 29630899
Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation.
Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Schemmer P, Werner J, Herr I., Int. J. Cancer 134(10), 2014
PMID: 24615157
Emerging Cellular Therapies for Cancer.
Guedan S, Ruella M, June CH., Annu. Rev. Immunol. 37(), 2018
PMID: 30526160
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.
Grinberg-Bleyer Y, Oh H, Desrichard A, Bhatt DM, Caron R, Chan TA, Schmid RM, Klein U, Hayden MS, Ghosh S., Cell 170(6), 2017
PMID: 28886380
Stem cells in cancer therapy: opportunities and challenges.
Zhang CL, Huang T, Wu BL, He WX, Liu D., Oncotarget 8(43), 2017
PMID: 29088907
Hallmarks of cancer: the next generation.
Hanahan D, Weinberg RA., Cell 144(5), 2011
PMID: 21376230
NF-κB, inflammation, immunity and cancer: coming of age.
Taniguchi K, Karin M., Nat. Rev. Immunol. 18(5), 2018
PMID: 29379212
Inflammation and colon cancer.
Terzic J, Grivennikov S, Karin E, Karin M., Gastroenterology 138(6), 2010
PMID: 20420949
Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action.
Marsden CG, Wright MJ, Pochampally R, Rowan BG., Methods Mol. Biol. 590(), 2009
PMID: 19763516
The resolution of inflammation: anti-inflammatory roles for NF-kappaB.
Lawrence T, Fong C., Int. J. Biochem. Cell Biol. 42(4), 2009
PMID: 20026420
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.
Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A., Cancer Res. 66(23), 2006
PMID: 17145890
Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9 upregulation.
Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, Zhu B., Stem Cells 30(10), 2012
PMID: 22887854
Oncogenic activation of NF-kappaB.
Staudt LM., Cold Spring Harb Perspect Biol 2(6), 2010
PMID: 20516126
Roles of NF-κB Signaling in the Regulation of miRNAs Impacting on Inflammation in Cancer.
Markopoulos GS, Roupakia E, Tokamani M, Alabasi G, Sandaltzopoulos R, Marcu KB, Kolettas E., Biomedicines 6(2), 2018
PMID: 29601548
miR-290 cluster modulates pluripotency by repressing canonical NF-κB signaling.
Luningschror P, Stocker B, Kaltschmidt B, Kaltschmidt C., Stem Cells 30(4), 2012
PMID: 22232084
MicroRNAs in pluripotency, reprogramming and cell fate induction.
Luningschror P, Hauser S, Kaltschmidt B, Kaltschmidt C., Biochim. Biophys. Acta 1833(8), 2013
PMID: 23557785
Identification of a cancer stem cell in human brain tumors.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB., Cancer Res. 63(18), 2003
PMID: 14522905
NF-kappaB and epithelial to mesenchymal transition of cancer.
Min C, Eddy SF, Sherr DH, Sonenshein GE., J. Cell. Biochem. 104(3), 2008
PMID: 18253935
The epithelial-mesenchymal transition generates cells with properties of stem cells.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA., Cell 133(4), 2008
PMID: 18485877
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T., J. Clin. Invest. 114(4), 2004
PMID: 15314694
New approach for understanding genome variations in KEGG.
Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M., Nucleic Acids Res. 47(D1), 2019
PMID: 30321428
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M., Science 270(5234), 1995
PMID: 7569976
β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells.
Schon S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT, Herbst A., Int. J. Cancer 135(8), 2014
PMID: 24623448
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast.
Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA., Cell 145(6), 2011
PMID: 21663795
Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways.
Luo K., Cold Spring Harb Perspect Biol 9(1), 2017
PMID: 27836834
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.
Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C., Clin. Cancer Res. 16(3), 2010
PMID: 20103663
Glioblastoma and other malignant gliomas: a clinical review.
Omuro A, DeAngelis LM., JAMA 310(17), 2013
PMID: 24193082
Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A., Acta Neuropathol. 129(6), 2015
PMID: 25943888
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.
Ellis HP, Greenslade M, Powell B, Spiteri I, Sottoriva A, Kurian KM., Front Oncol 5(), 2015
PMID: 26636033
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bahr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schafer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society., Lancet 393(10172), 2019
PMID: 30782343
Residual tumor cells are unique cellular targets in glioblastoma.
Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, Garbe S, Steinfarz B, Pietsch T, Steindler DA, Schramm J, Herrlinger U, Brustle O, Scheffler B., Ann. Neurol. 68(2), 2010
PMID: 20695020
A paired comparison between glioblastoma "stem cells" and differentiated cells.
Schneider M, Strobele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, Hasslacher S, Enzenmuller S, Strauss G, Baumann B, Karpel-Massler G, Westhoff MA, Debatin KM, Halatsch ME., Int. J. Cancer 138(7), 2015
PMID: 26519239
Heterogeneity maintenance in glioblastoma: a social network.
Bonavia R, Inda MM, Cavenee WK, Furnari FB., Cancer Res. 71(12), 2011
PMID: 21628493
The evolving landscape of glioblastoma stem cells.
Yan K, Yang K, Rich JN., Curr. Opin. Neurol. 26(6), 2013
PMID: 24152818
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.
Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE., Cell 157(3), 2014
PMID: 24726434
Targeting Aggressive Cancer Stem Cells in Glioblastoma.
Seymour T, Nowak A, Kakulas F., Front Oncol 5(), 2015
PMID: 26258069
Asymmetric stem cell division in development and cancer.
Caussinus E, Hirth F., Prog. Mol. Subcell. Biol. 45(), 2007
PMID: 17585502
Cancer stem cells in glioblastoma.
Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN., Genes Dev. 29(12), 2015
PMID: 26109046
NF-κB Signalling in Glioblastoma.
Soubannier V, Stifani S., Biomedicines 5(2), 2017
PMID: 28598356
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators, Butowski N, Campian J, Recht L, Lim M, Ashby L, Drappatz J, Hirte H, Iwamoto F, Mechtler L, Goldlust S, Becker K, Barnett G, Nicholas G, Desjardins A, Benkers T, Wagle N, Groves M, Kesari S, Horvath Z, Merrell R, Curry R, O'Rourke J, Schuster D, Wong M, Mrugala M, Jensen R, Trusheim J, Lesser G, Belanger K, Sloan A, Purow B, Fink K, Raizer J, Schulder M, Nair S, Peak S, Perry J, Brandes A, Weller M, Mohile N, Landolfi J, Olson J, Finocchiaro G, Jennens R, DeSouza P, Robinson B, Crittenden M, Shih K, Flowers A, Ong S, Connelly J, Hadjipanayis C, Giglio P, Mott F, Mathieu D, Lessard N, Sepulveda SJ, Lovey J, Wheeler H, Inglis PL, Hardie C, Bota D, Lesniak M, Portnow J, Frankel B, Junck L, Thompson R, Berk L, McGhie J, Macdonald D, Saran F, Soffietti R, Blumenthal D, Andre de SBCM, Nowak A, Singhal N, Hottinger A, Schmid A, Srkalovic G, Baskin D, Fadul C, Nabors L, LaRocca R, Villano J, Paleologos N, Kavan P, Pitz M, Thiessen B, Idbaih A, Frenel JS, Domont J, Grauer O, Hau P, Marosi C, Sroubek J, Hovey E, Sridhar PS, Cher L, Dunbar E, Coyle T, Raymond J, Barton K, Guarino M, Raval S, Stea B, Dietrich J, Hopkins K, Erridge S, Steinbach JP, Pineda LE, Balana QC, Sonia Del BB, Wenczl M, Molnar K, Hideghety K, Lossos A, Myra van L, Levy A, Harrup R, Patterson W, Lwin Z, Sathornsumetee S, Lee EJ, Ho JT, Emmons S, Duic JP, Shao S, Ashamalla H, Weaver M, Lutzky J, Avgeropoulos N, Hanna W, Nadipuram M, Cecchi G, O'Donnell R, Pannullo S, Carney J, Hamilton M, MacNeil M, Beaney R, Fabbro M, Schnell O, Fietkau R, Stockhammer G, Malinova B, Odrazka K, Sames M, Miguel Gil G, Razis E, Lavrenkov K, Castro G, Ramirez F, Baldotto C, Viola F, Malheiros S, Lickliter J, Gauden S, Dechaphunkul A, Thaipisuttikul I, Thotathil Z, Ma HI, Cheng WY, Chang CH, Salas F, Dietrich PY, Mamot C, Nayak L, Nag S., Lancet Oncol. 18(10), 2017
PMID: 28844499
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.
Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB., Genes Dev. 31(12), 2017
PMID: 28724615
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.
Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, Rich JN., Stem Cells 27(10), 2009
PMID: 19658188
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.
Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z., Mol. Cell 48(5), 2012
PMID: 23123196
Targeting A20 decreases glioma stem cell survival and tumor growth.
Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN., PLoS Biol. 8(2), 2010
PMID: 20186265
NFKBIA deletion in glioblastomas.
Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR 4th., N. Engl. J. Med. 364(7), 2010
PMID: 21175304
Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma.
Happold C, Stojcheva N, Silginer M, Weiss T, Roth P, Reifenberger G, Weller M., J. Neurochem. 144(6), 2018
PMID: 29480969
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group., N. Engl. J. Med. 352(10), 2005
PMID: 15758009
Cancer stem cell division: when the rules of asymmetry are broken.
Mukherjee S, Kong J, Brat DJ., Stem Cells Dev. 24(4), 2014
PMID: 25382732
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R., N. Engl. J. Med. 352(10), 2005
PMID: 15758010
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hanel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tuttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M., J. Clin. Oncol. 34(14), 2016
PMID: 26976423
Neural stem cells adopt tumorigenic properties by constitutively activated NF-kappaB and subsequent VEGF up-regulation.
Kaus A, Widera D, Kassmer S, Peter J, Zaenker K, Kaltschmidt C, Kaltschmidt B., Stem Cells Dev. 19(7), 2010
PMID: 20184430
Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles.
Treps L, Perret R, Edmond S, Ricard D, Gavard J., J Extracell Vesicles 6(1), 2017
PMID: 28815003
Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ., N. Engl. J. Med. 377(20), 2017
PMID: 29141164
Sustained NF-κB-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition.
da Hora CC, Pinkham K, Carvalho L, Zinter M, Tabet E, Nakano I, Tannous BA, Badr CE., Cell Death Discov 5(), 2019
PMID: 30854231
Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation.
Man J, Shoemake J, Zhou W, Fang X, Wu Q, Rizzo A, Prayson R, Bao S, Rich JN, Yu JS., Cell Rep 9(5), 2014
PMID: 25464848
IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.
Rinkenbaugh AL, Cogswell PC, Calamini B, Dunn DE, Persson AI, Weiss WA, Lo DC, Baldwin AS., Oncotarget 7(43), 2016
PMID: 27732951
NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype.
Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J., Nat Commun 4(), 2013
PMID: 23934482
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.
Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, Ladner K, Furuta T, Sabit H, Chhipa R, Cho JH, Mohyeldin A, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng SY, Lee LJ, Nakada M, Guttridge D, DasGupta B, Goidts V, Bhat KP, Nakano I., Cancer Cell 29(2), 2016
PMID: 26859459
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R., Neuro-oncology 17(1), 2014
PMID: 25140036
Advances in the molecular genetics of gliomas - implications for classification and therapy.
Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M., Nat Rev Clin Oncol 14(7), 2016
PMID: 28031556
Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression.
Beck S, Jin X, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Nam DH, Choi YJ, Kim H., Mol. Cells 31(1), 2010
PMID: 21193962
American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS., Neuro-oncology 18 Suppl 1(), 2016
PMID: 26705298
The treatment of glioblastoma multiforme of the brain.
Jelsma R, Bucy PC., J. Neurosurg. 27(5), 1967
PMID: 4293835
Standards of care for treatment of recurrent glioblastoma--are we there yet?
Weller M, Cloughesy T, Perry JR, Wick W., Neuro-oncology 15(1), 2012
PMID: 23136223
Leukaemia stem cells and the evolution of cancer-stem-cell research.
Huntly BJ, Gilliland DG., Nat. Rev. Cancer 5(4), 2005
PMID: 15803157
Integrating cell-signalling pathways with NF-kappaB and IKK function.
Perkins ND., Nat. Rev. Mol. Cell Biol. 8(1), 2007
PMID: 17183360
Cancer stem cells in nervous system tumors.
Singh SK, Clarke ID, Hide T, Dirks PB., Oncogene 23(43), 2004
PMID: 15378086
Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications.
Abou-Antoun TJ, Hale JS, Lathia JD, Dombrowski SM., Neurotherapeutics 14(2), 2017
PMID: 28374184
Cancerous stem cells can arise from pediatric brain tumors.
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI., Proc. Natl. Acad. Sci. U.S.A. 100(25), 2003
PMID: 14645703
C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.
Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R, White E, Tang B, Orisme W, Gupta K, Rusch M, Chen X, Li Y, Nagahawhatte P, Hedlund E, Finkelstein D, Wu G, Shurtleff S, Easton J, Boggs K, Yergeau D, Vadodaria B, Mulder HL, Becksfort J, Becksford J, Gupta P, Huether R, Ma J, Song G, Gajjar A, Merchant T, Boop F, Smith AA, Ding L, Lu C, Ochoa K, Zhao D, Fulton RS, Fulton LL, Mardis ER, Wilson RK, Downing JR, Green DR, Zhang J, Ellison DW, Gilbertson RJ., Nature 506(7489), 2014
PMID: 24553141
Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway.
Pietsch T, Wohlers I, Goschzik T, Dreschmann V, Denkhaus D, Dorner E, Rahmann S, Klein-Hitpass L., Acta Neuropathol. 127(4), 2014
PMID: 24562983
A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.
Ozawa T, Arora S, Szulzewsky F, Juric-Sekhar G, Miyajima Y, Bolouri H, Yasui Y, Barber J, Kupp R, Dalton J, Jones TS, Nakada M, Kumabe T, Ellison DW, Gilbertson RJ, Holland EC., Cell Rep 23(13), 2018
PMID: 29949764
Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons.
Kaltschmidt C, Kaltschmidt B, Baeuerle PA., Proc. Natl. Acad. Sci. U.S.A. 92(21), 1995
PMID: 7568184
NF-kappaB in the nervous system.
Kaltschmidt B, Kaltschmidt C., Cold Spring Harb Perspect Biol 1(3), 2009
PMID: 20066105
Global cancer statistics.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., CA Cancer J Clin 61(2), 2011
PMID: 21296855
Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer.
Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, Beral V, Boyle P, Trichopoulos D., Int. J. Cancer 49(1), 1991
PMID: 1874569
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA., J. Natl. Cancer Inst. 98(23), 2006
PMID: 17148771
Hereditary ovarian cancer. Heterogeneity in age at onset.
Lynch HT, Watson P, Lynch JF, Conway TA, Fili M., Cancer 71(2 Suppl), 1993
PMID: 8420679
NF-κB is a critical mediator of BRCA1-induced chemoresistance.
Harte MT, Gorski JJ, Savage KI, Purcell JW, Barros EM, Burn PM, McFarlane C, Mullan PB, Kennedy RD, Perkins ND, Harkin DP., Oncogene 33(6), 2013
PMID: 23435429
NF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes.
Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S, Wiesmuller L., Nucleic Acids Res. 40(1), 2011
PMID: 21908405
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ., J. Clin. Oncol. 23(31), 2005
PMID: 16258091
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ., J. Clin. Oncol. 20(5), 2002
PMID: 11870167
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM., Obstet Gynecol 61(4), 1983
PMID: 6828269
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM., Lancet 386(9990), 2015
PMID: 26002111

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 31083587
PubMed | Europe PMC

Suchen in

Google Scholar